ArticleHemaSphere2022

Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases.

Davor Galusic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.